Clinical trial
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are currently enrolled in PCI-32765 studies that have been completed according to the parent protocol, are actively receiving treatment with PCI-32765, and who continue to benefit from PCI-32765 treatment.
| Category | Value |
|---|---|
| Date last updated at source | 2017-05-04 |
| Study type(s) | Interventional |
| Expected enrolment | 700 |
| Study start date | 2013-09-09 |
| Estimated primary completion date | 2021-12-29 |